Status:
COMPLETED
ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty
Lead Sponsor:
Seoul Medical Center
Conditions:
Spinal Anesthesia
Total Knee Replacement Arthroplasty
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
This prospective randomized double-blind dose-response study is aimed to investigate the ED50 and ED95 of intrathecal bupivacaine with or without epinephrine 100 mcg for total knee replacement arthrop...
Detailed Description
Patients undergoing total knee replacement arthroplasty are randomly assigned to six bupivacaine dose group (6, 7, 8, 9, 10, 11 mg). Combined spinal-epidural anesthesia would be performed. The dose wo...
Eligibility Criteria
Inclusion
- The patients with ASA class I or II scheduled for total knee replacement surgery
Exclusion
- Patients with previous spine surgery, diabetic and other neuropathy, skin infection at the site of injection, allergy to bupivacaine and other common contraindications for spinal anesthesia were excluded from this study.
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT01264575
Start Date
December 1 2009
End Date
January 1 2011
Last Update
January 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul Medical Center
Seoul, South Korea, 135-740